Sabinsa Corporation Expands Manufacturing Facilities

Sami Labs Limited, Sabinsa's research and manufacturing arm based in Bangalore, India, currently has four manufacturing facilities in that area. These include production facilities for bulk extracts and specialty chemicals, a fermentation unit, tissue culture laboratories and a supercritical fluid extraction facility.

To meet the increasing demand for Sabinsa's branded phytonutrient ingredients

as well as the growing interest in custom synthesis of active pharmaceutical ingredients (APIs) and aroma chemicals worldwide, three new manufacturing facilities have been added to the company's infrastructure. These facilities specifically dedicated to phytonutrients, APIs and aroma chemicals are scheduled to become operational in July/August 2005. In addition, three new production units -one for specialty fine chemicals and two for phytochemicals/ plant-based extracts are expected to be operational in the second quarter of 2006.

"Although APIs now constitute less than 10 percent of our sales, it is certainly a high-growing segment for us," says Sendhil Pani , manager special projects, marketing, with Sabinsa. "The new facilities will be used to increase manufacturing capacity for selected phytonutrients, other nutritional ingredients and aroma chemicals, as well as add to our capabilities in custom synthesis for the pharmaceutical market."

The core of Sabinsa 's strength in custom synthesis is the company's expertise in phytochemistry. As summarized by Sendhil Pani "Our technological ability to isolate active ingredients from natural sources is the key. Once identified, isolated and purified, these compounds are used as the basis of nutritional ingredients. But we can also isolate those actives as a pharmaceutical ingredient or intermediate and employ our capabilities in chemical process and development to manufacture those compounds." Included in this list are chiral amino acids, other chiral molecules, seleno amino acids, heterocyclic compounds, peptides and steroidal compounds.

A Selenium SeLECT® : SUPERIOR BIOAVAILABILITY

A recent study conducted by Vanderbilt University Medical Center found that Selenium SeLECT , Sabinsa's branded L-(+)-Selenomethionine, is twice as bioavailable as selenium in the form of selenite.

"This study further confirms that not all forms of selenium are equal, and that selenomethionine, specifically our Selenium SeLECT, is more available to be absorbed and used by the body," stated Todd Norton, president, Sabinsa Corporation. Dr. Vladimir Badmaev, Sabinsa's vice president of scientific and medical affairs adds, "the University is in the process of preparing for three additional studies using Selenium SeLECT and we look forward to hearing about the results of those studies."

The study entitled "Effectiveness of selenium supplements in a low-selenium area of China " was published in the April 1, 2005 issue of the American Journal of Clinical Nutrition. The study involved 120 subjects with an average selenium intake of 10 micrograms per day, well below the recommended dietary allowance of 55 micrograms per day. Participants were given supplemental selenium in either the form of sodium selenite or selenomethionine (Selenium SeLECT was used). The amount of selenium in both forms needed to optimize nutrient levels in the blood was determined. As compared to sodium selenite, less than half the amount of selenium as selenomethionine was needed to reach optimal blood levels.

Selenomethionine, a "molecularly integrated" organic compound is the predominant form of naturally occurring selenium found in foods. The current study confirms that this form of selenium is more than twice as available to be absorbed and used by the body than the inorganic selenium supplement, sodium selenite. The authors plan to publish an additional paper on the results.

Sabinsa's Selenium SeLECT is currently the focus of a large-scale prostate cancer study funded through the National Institute of Health's (NIH) National Cancer Institute (NCI). It is the only selenium source being administered in the study. A second study being performed in conjunction with this study seeks to evaluate selenomethionine's beneficial role in the prevention of Alzheimer's disease.

The United States Pharmacopeial (USP) monograph for Selenomethionine is based on Sabinsa's Selenium SeLECT brand of L-(+)-Selenomethionine.

Joint Presentation by Dr. Vladimir Badmaev and Dr. Richard Passwater at Supplyside East

A joint presentation by Dr. Vladimir Badmaev, VP Medical and Scientific Affairs, Sabinsa Corporation and Dr. Richard A Passwater, noted industry expert, features in the Vendorworks segment of the SupplySide East trade show. The presentation titled "Bioavailability of Selenium a Key Factor in its Nutritional and Therapeutic Use" is scheduled in Room 344 of the Baltimore Convention Center , Baltimore , Maryland on May 6, 2005, at 9 a.m. We look forward to meeting you there.

Sabinsa Gets European Patent for Forslean®

Sabinsa Corporation recently received a European patent for the use of forskolin in supporting weight management. The patent number 98 907 537 9 titled "Forskolin for Promoting Lean Body Mass" covers the use of ForsLean, Sabinsa's branded Coleus forskohlii extract as a dietary supplement to promote lean body mass. Use of ForsLean helps in shifting the proportion of body mass in favor of lean body mass, reducing fat tissue and encouraging weight loss.

Sabinsa intends to make the use of the claims in this patent (#98 907 5379), along with the use of the patent number, available to dietary supplement manufacturers and marketers in Europe through a non-exclusive licensing agreement. This patent

encompasses all European countries. It ensures that customers in Europe are receiving Sabinsa's quality Coleus forskohlii extract, and it offers them legal protection and rights for Sabinsa's intellectual property in Europe .

COSMETIC CORNER

Our dedicated cosmeceuticals website is now up and running!

www.sabinsacosmetics.com .

Happy browsing!....and we look forward to your comments and feedback.

Sabinsa Corporation participated in In -Cosmetics 2005, held in Berlin , Germany April 12-15. The show, described as the "only truly international industry event" drew 3,040 visitors representing over 74 countries.

Tasneen Padiath (right) Manager-Business Development & Kavita Subramanian Sr. Manager of International Business in the Sabinsa booth at the show

TRADESHOWS:

Sabinsa Corporation will participate in the following upcoming industry events:

Supply Side East 2005
May 4-6
Baltimore , Maryland

Vitafoods Show 2005
May 10-12
Geneva , Switzerland

NYSCC 2005
May 10-11
Secaucus , New Jersey

ChemSpec Europe, 2005
June 22-23
Dusseldorf , Germany

PRODUCT ADS

HAPPI, Soap, Perfumery & Cosmetics, Cosmetics & Toiletries, Natural Products Insider, Chemical Market Reporter.